Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Array BioPharma Is Surging Today

By Cory Renauer - May 21, 2019 at 12:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive clinical trial results gave investors a reason to cheer.

What happened

Shares of Array BioPharma (ARRY), a commercial-stage biopharmaceutical company, are on the move following positive results from a pivotal cancer trial. Investors looking forward to increasing sales of Array's first two drugs have pushed the stock up 16.8% as of 12:19 p.m. EDT on Tuesday. 

So what 

Last June, the FDA approved the use of Braftovi plus Mektovi for the treatment of advanced melanoma patients with BRAF-mutated tumors, and during the nine months ended March 31, sales reached an impressive $71.8 million. Over the same time frame, Array received $101 million in collaboration and license revenue from Novartis (NVS 0.22%) and Loxo Oncology, which is now an Eli Lilly (LLY 3.20%) company. Braftovi plus Mektovi sales will probably keep climbing because adding this combination to Erbitux significantly improved patients' chances at long-term survival during the pivotal Beacon study.  

The happiest person you've ever seen working in a lab.

Image source: Getty Images.

The Beacon trial enrolled 615 patients with BRAF-mutant colorectal cancer who have relapsed at least once. Patients receiving Array's two-drug combo plus Erbitux exhibited a risk of death 48% lower than those receiving the standard treatment as a monotherapy. We also know that 26.1% of patients responded to what Array is calling the Braftovi Triplet while just 1.9% of patients responded to Erbitux on its own.

Now what

The company expects to submit an application to treat advanced colorectal cancer patients with the Braftovi Triplet in the second half of the year. Last summer the FDA granted the Braftovi Triplet a breakthrough therapy designation that should shorten its upcoming review from 10 months to six, which means Array could post some big revenue gains again in 2020. 

Colorectal cancer claims the lives of around 700,000 people globally each year, and patients who don't respond to their first round of treatment don't have a lot of options. With a clear survival benefit, annual sales of Array's triplet could reach more than $500 million in 2023. That would be more than enough to help this biotech reach profitability and to drive the stock much higher down the road.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Array Technologies, Inc. Stock Quote
Array Technologies, Inc.
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$323.48 (3.20%) $10.02
Novartis AG Stock Quote
Novartis AG
$91.46 (0.22%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.